This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Study to Evaluate Safety and Daytime Sedation in S...
Clinical trial

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Read time: 2 mins
Last updated:23rd Oct 2019
Identifier: NCT04164758

This is a pilot, hypothesis-generating study to explore the effects of pimavanserin and low-dose quetiapine in subjects with Parkinson's disease with neuropsychiatric symptoms.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Actual Study Start Date: October 23, 2019
Estimated Primary Completion Date: November 2020
Estimated Study Completion Date: December 2020

Arms:
- Experimental:
Drug - pimavanserin
- Placebo Comparator: Placebo
- Active Comparator: Quetiapine

Category Value
Date last updated at source 2019-11-15
Study type(s) Interventional
Expected enrolment 60
Study start date 2019-10-23
Estimated primary completion date 2020-11-01

View full details